The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Table 1
Baseline characteristics before and after propensity score matching.
Unmatched cohort ()
Matched cohort ()
DPP4i ()
GLP1Ra ()
value
DPP4i ()
GLP1Ra ()
value
Standardized difference
Age (years)
<0.001
0.55
0.09
Gender (male)
220 (65%)
65 (66%)
0.92
58 (67%)
58 (67%)
1.0☨
0.02
BW (kg)
<0.001
0.86
0.02
BMI (kg/m2)
0.01
0.99
<0.01
SBP (mmHg)
0.19
0.65
0.06
DBP (mmHg)
0.002
0.84
0.02
HbA1c (mmol/mol (%))
()
()
<0.001
()
()
0.88
0.02
eGFR (mL/min/1.73 m2)
0.04
0.91
0.03
CCr (mL/min)
0.001
0.81
0.04
ACR (μg/gCr)
12.7 [6.3, 93.1]
18.0 [18.0, 145.1]
0.04
39.6 [13.0, 140.5]
41.6 [15.1, 145.7]
0.23
LNACR
0.04
0.46
0.11
Duration of treatment (months)
0.50
0.36
0.14
Types of SGLT2 inhibitor
Ipragliflozin
77 (23%)
21 (21%)
0.74
19 (22%)
21 (24%)
0.47☨
0.15
Dapagliflozin
57 (17%)
14 (14%)
0.52
11 (13%)
11 (13%)
0.21☨
0.23
Tofogliflozin
33 (10%)
18 (18%)
0.02
12 (14%)
14 (16%)
1.0☨
0.03
Luseogliflozin
29 (9%)
8 (8%)
0.88
8 (9%)
8 (9%)
0.61☨
0.12
Canagliflozin
45 (13%)
10 (10%)
0.40
11 (13%)
9 (11%)
0.52☨
0.14
Empagliflozin
51 (15%)
9 (9%)
0.13
7 (8%)
8 (9%)
1.0☨
0.0
SGLT2i changed during treatment
46 (14%)
19 (19%)
0.17
18 (21%)
15 (17%)
0.47☨
0.15
Concomitant treatment (at survey)
Metformin
212 (63%)
73 (75%)
0.04
61 (71%)
62 (72%)
0.46☨
0.14
SU
122 (36%)
36 (36%)
0.96
29 (34%)
32 (37%)
0.87☨
0.05
Insulin
84 (25%)
42 (42%)
0.001
31 (36%)
33 (38%)
0.87☨
0.05
Pioglitazone
78 (23%)
15 (15%)
0.09
14 (16%)
14 (16%)
0.66☨
0.10
RAS inhibitors
172 (51%)
59 (60%)
0.13
47 (55%)
49 (57%)
1.0☨
0.02
Ca channel blocker
157 (46%)
39 (39%)
0.21
32 (37%)
34 (40%)
0.75☨
0.07
Β blocker
44 (13%)
15 (15%)
0.59
13 (15%)
14 (16%)
1.0☨
0.0
Statins
212 (63%)
62 (63%)
0.99
51 (59%)
54 (63%)
1.0☨
0.02
Values are shown as the or /total (%). values by an unpaired -test or chi-square test with the unmatched cohort model and paired -test and ☨McNemar’s test with the matched cohort model. ※95% confidence interval of the logarithmic value of the odds ratio calculated by the Mantel-Haenszel method. ¶SGLT2 inhibitor changed during the study period. BW: body weight; BMI: body mass index; CCr: creatinine clearance; DPP4: dipeptidyl peptidase-4; eGFR: estimated glomerular filtration; GLP1RA: glucagon-like peptide 1 receptor agonist; LNACR: logarithmic value of albumin-to- creatinine ratio; MAP: mean arterial pressure; RAS: renin-angiotensin system inhibitor; SGLT2: sodium-glucose cotransporter.
